The first edition of the European LeukemiaNet (ELN) recommendations for diagnosis and
management of acute myeloid leukemia (AML) in adults, published in 2010, has found …

Relapse remains the main cause of treatment failure in acute myeloid leukemia (AML)
undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). Emerging …

This study investigated the efficacy and safety of azacitidine maintenance in the
posttransplant setting based on the encouraging phase 1/2 reports for azacitidine …

PURPOSE Outcomes are poor in TP53-mutant (m TP53) acute myeloid leukemia (AML) and
myelodysplastic syndromes (MDS), even after allogeneic hematopoietic stem-cell transplant …

PURPOSE Relapse is a major cause of treatment failure after allogeneic hematopoietic stem-
cell transplantation (allo-HSCT) for high-risk acute myeloid leukemia (HR-AML). The aim of …

Acute myeloid leukemia (AML) is a phenotypically and prognostically heterogeneous
hematopoietic stem cell disease that may be cured in eligible patients with intensive …

Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are usually associated
with poor outcomes, especially in high‐risk AML/MDS. Allogeneic hematopoietic stem cell …

Curative treatment in acute myeloid leukemia (AML) depends on successful induction
therapy to achieve a complete remission (CR), and subsequent post‐remission therapy to …

Thirty patients, with high-risk acute myeloid leukemia (AML, n= 20) or myelodysplastic
syndrome (MDS, n= 10), were enrolled in a phase II trial entailing prophylactic post …

Mutations in the essential tumor suppressor gene, TP53, are observed in only 5–10% of
acute myeloid leukemia (AML) cases, but are highly associated with therapy-related AML …